Mekinist

by GlaxoSmithKline (GSK)

Mekinist is a MEK inhibitor used in combination with Tafinlar for BRAF-mutant melanoma and other solid tumors, available through the GSK Patient Assistance Program.

What is Mekinist?

Mekinist (trametinib) is a MEK1/MEK2 kinase inhibitor used in combination with Tafinlar (dabrafenib) to treat multiple BRAF V600 mutation-positive cancers:

  • Unresectable or metastatic melanoma with BRAF V600E or V600K mutations
  • Adjuvant treatment of melanoma with BRAF V600E or V600K mutations after complete resection
  • Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation
  • Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation
  • Solid tumors with BRAF V600E mutation that progressed after prior treatment (tumor-agnostic)

The combination of BRAF and MEK inhibition provides more complete blockade of the MAPK pathway that drives tumor cell growth. Mekinist is taken once daily as an oral tablet.

Patient Assistance Program

Eligible patients may receive Mekinist at no cost through the GSK Patient Assistance Program. ClariMeds handles all application paperwork on your behalf.

Eligibility

  • U.S. resident with a valid prescription from a licensed oncologist
  • Confirmed BRAF V600 mutation
  • Uninsured or underinsured
  • Meets household income requirements

Patient assistance programs

GSK Patient Assistance Program

Manufacturer PAP
Eligibility
Uninsured or underinsured U.S. residents with BRAF V600-mutant cancer and a valid Mekinist prescription who meet income requirements.
Income limit
Varies based on household size; generally ≤400% of Federal Poverty Level (FPL)
Insurance
Uninsured or underinsured
How to apply
Apply through ClariMeds — we handle all paperwork at no cost to you. Applications are submitted directly to GSK on your behalf.

Need help applying?

ClariMeds handles the entire application process for you — for free. See if you qualify in minutes.

See If You Qualify — Free